Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics Inc. (symbol: CORT) is a pioneering pharmaceutical company focused on the discovery and development of medications that modulate the effects of cortisol to treat severe metabolic, oncologic, and neuropsychiatric disorders. Since its inception, Corcept has dedicated itself to understanding and mitigating the adverse effects of excess cortisol, which plays a role in a variety of diseases.
The company has made significant strides in this field by developing over 300 proprietary molecules. These compounds competitively block the glucocorticoid receptor (GR) without affecting the progesterone receptor. Scientific studies suggest that GR antagonism may help treat conditions such as post-traumatic stress disorder, mild cognitive impairment, Alzheimer's disease, and alcoholism.
Corcept's flagship product, mifepristone, is already making an impact in the market. Additionally, the company continues to advance the most promising compounds from its extensive pipeline into clinical trials to assess their potential in mitigating the effects of excess cortisol and treating serious, sometimes life-threatening conditions.
Corcept's recent achievements include a series of successful clinical trials and partnerships that have bolstered its position in the pharmaceutical industry. Financially, the company is on stable ground, allowing it to invest further in research and development to expand its portfolio of effective treatments.
As a commercial-stage company, Corcept Therapeutics is committed to bringing innovative treatments to market, guided by a deep understanding of cortisol’s role in various diseases. Investors and healthcare professionals alike are keenly watching Corcept for its continued contributions to medical science and patient care.
For the latest updates on Corcept Therapeutics, including performance, events, and developments, please visit their official website or contact their investor relations team.
Corcept Therapeutics (NASDAQ: CORT) announced updates on its proprietary selective cortisol modulator, miricorilant, targeting antipsychotic-induced weight gain (AIWG) and non-alcoholic steatohepatitis (NASH). The trials for AIWG showed no reversal of weight gain, though miricorilant was effective in reducing liver fat in ongoing NASH studies. Promising results from pre-clinical and Phase 1 studies suggest potential further investigation into preventing AIWG. The company plans to conduct a Phase 2 trial next year for NASH.
Corcept Therapeutics (CORT) reported Q3 2022 revenue of $101.7 million, up from $96.1 million in Q3 2021. The company tightened its 2022 revenue guidance to $400 - $410 million. Net income increased to $34.6 million or $0.30 per share. However, revenue was impacted by reduced in-person physician interactions post-pandemic. Corcept is optimistic about ongoing clinical trials, particularly for treatments targeting Cushing's syndrome and ALS, with upcoming significant readouts expected.
Corcept Therapeutics (NASDAQ: CORT) will report its third-quarter financial results and provide a corporate update on November 3, 2022. A conference call is scheduled for 5:00 p.m. ET, where participants will need to register in advance. Corcept is known for its proprietary compounds that modulate cortisol effects, targeting numerous serious conditions, including Cushing’s syndrome and various cancers. The company’s drug, Korlym®, is FDA-approved for Cushing’s syndrome.
Corcept Therapeutics (NASDAQ: CORT) has initiated DAZALS, a Phase 2 trial evaluating its cortisol modulator, dazucorilant, for treating ALS (amyotrophic lateral sclerosis). The 198-patient, randomized, double-blind, placebo-controlled study aims to assess the drug's efficacy in improving ALS symptoms and safety. Dazucorilant has shown promising results in animal models, enhancing motor performance and reducing neuroinflammation. This partnership with TRICALS, an ALS academic consortium in Europe, highlights Corcept's commitment to addressing the unmet needs in ALS treatment.
Corcept Therapeutics (CORT) reported Q2 2022 revenue of $103.4 million, an increase from $91.6 million in Q2 2021. The company reiterated its 2022 revenue guidance of $400 - $430 million. Net income for the quarter was $27.4 million or $0.24 per share, up from $0.21 in the prior year. Cash and investments rose to $382.0 million, reflecting solid growth. Corcept continues to advance clinical trials for relacorilant, addressing conditions such as platinum-resistant ovarian cancer and Cushing’s syndrome, with completion of multiple Phase 2 trials expected by year-end.
Corcept Therapeutics (NASDAQ: CORT) will report its second quarter financial results and provide a corporate update on August 3, 2022, with a conference call at 5:00 p.m. ET. The company has a robust portfolio of proprietary compounds targeting cortisol modulation for severe disorders, including Cushing’s syndrome and cancers. They are also working on clinical trials for other conditions. The call will be accessible through registration, and a replay will be available on their website.
Corcept Therapeutics announced the initiation of the ROSELLA Phase 3 trial for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer. The previous Phase 2 trial demonstrated improved progression-free survival, duration of response, and overall survival without increasing side effects. The pivotal trial aims to enroll 360 women and is critical as limited treatment options exist for this patient population. Success could establish relacorilant as a new standard of care.
Corcept Therapeutics has announced the initiation of a registrational Phase 3 trial for relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. The decision follows a successful Phase 2 study showing significant improvements in progression-free survival, duration of response, and overall survival without added side effects. The new trial, named ROSELLA, aims to enroll 360 women and is designed to replicate the positive outcomes observed previously. Results will be presented at the ASCO Annual Meeting.
Corcept Therapeutics (NASDAQ: CORT) reported Q1 2022 results with revenue of $93.7 million, up from $79.4 million in Q1 2021. The diluted net income per share rose to $0.20, compared to $0.18 a year earlier. The company reiterated its 2022 revenue guidance of $400 - $430 million. Cash and investments increased to $368.1 million as of March 31, 2022. Corcept is advancing multiple clinical trials, notably in platinum-resistant ovarian cancer and Cushing’s syndrome, with a pivotal trial expected soon. A conference call was held on May 5, 2022.
Corcept Therapeutics (NASDAQ: CORT) will report its first quarter financial results on May 5, 2022, followed by a corporate update and a conference call at 5:00 p.m. ET. The company specializes in cortisol modulation and has developed a portfolio of proprietary compounds for serious disorders, including Cushing's syndrome. Korlym®, its flagship drug, was the first FDA-approved treatment for Cushing's. Details for joining the call are provided, ensuring access for investors and stakeholders.
FAQ
What is the current stock price of Corcept Therapeutics (CORT)?
What is the market cap of Corcept Therapeutics (CORT)?
What does Corcept Therapeutics Inc. do?
What is the primary focus of Corcept Therapeutics' research?
What are some of the conditions Corcept's products aim to treat?
What is mifepristone?
How many proprietary molecules has Corcept developed?
Does Corcept Therapeutics have any ongoing clinical trials?
Are there any recent achievements by Corcept Therapeutics?
What is the financial condition of Corcept Therapeutics?
How can I get the latest updates on Corcept Therapeutics?
What role does cortisol play in diseases?
